Ulcerative Colitis
1,154
142
193
561
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
198 trials with published results (17%)
Research Maturity
561 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.5%
133 terminated out of 1154 trials
80.8%
-5.7% vs benchmark
19%
218 trials in Phase 3/4
35%
198 of 561 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 561 completed trials
Clinical Trials (1154)
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
Combination CurQD and Vedolizumab in Ulcerative Colitis
A Specific Probiotic in thE MOdulation of Gut Microbiota of patieNts With Mild-to-modErate Ulcerative Colitis
Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Treatment of UC With Novel Therapeutics
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
GI Permeability Change in Response to Aquamin®